📊 ALMS Key Takeaways
Is Alumis Inc.. (ALMS) a Good Investment?
ALUMIS is an early-stage pharmaceutical company with minimal revenue ($1.7M) and massive operating losses (-$98.4M), coupled with negative operating cash flow of -$87.1M. While the strong balance sheet ($567M equity, $63.9M cash) provides operational runway of 1-2 years, the company lacks demonstrated profitability or clear revenue trajectory from available fundamentals.
Alumis shows extremely weak current fundamentals, with minimal revenue relative to its cost base, deeply negative operating and net margins, and nearly $300M of annual free cash outflow. The balance sheet is a mitigating factor because liquidity is strong and leverage is negligible, but the business still depends on translating pipeline spending into durable revenue before cash burn materially erodes that cushion.
Alumis Inc.. Key Strengths (ALMS)
- Strong balance sheet with $567M stockholders' equity and effectively zero debt
- Substantial cash reserves of $63.9M providing runway for continued R&D operations
- Excellent liquidity position with 7.51x current ratio limiting near-term financial distress risk
- Strong liquidity with a 6.01x current ratio and meaningful cash relative to liabilities
- No meaningful balance-sheet leverage, reducing refinancing and solvency pressure
- Positive reported revenue indicates at least some non-zero commercial or collaboration inflow
ALMS Stock Risks: Alumis Inc.. Investment Risks
- Massive operating losses of -$98.4M against only $1.7M revenue indicates unsustainable burn rate unsupported by revenue
- Negative operating cash flow of -$87.1M will deplete reserves within 12-18 months if business model does not change
- No demonstrated commercialization path or profitability timeline visible from available financial data; company appears in early R&D phase with unproven pipeline
- Operating model is highly unprofitable, with operating margin of -1615.5% and net margin of -679.9%
- Cash burn is severe, with operating cash flow of -$297.62M and free cash flow of -$298.27M
- Growth quality is weak because revenue remains far too small to support the current expense base
Key Metrics to Watch
- Quarterly revenue growth and clinical trial progression for lead pipeline candidates
- Monthly operating cash burn rate and projected runway remaining
- Gross margin evolution as company transitions from R&D to commercialization phase
- Quarterly operating cash burn versus cash and equivalents
- Revenue scale-up and operating expense discipline
Alumis Inc.. (ALMS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.51x current ratio provides a solid financial cushion.
ALMS Profit Margin, ROE & Profitability Analysis
ALMS vs Healthcare Sector: How Alumis Inc.. Compares
How Alumis Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alumis Inc.. Stock Overvalued? ALMS Valuation Analysis 2026
Based on fundamental analysis, Alumis Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alumis Inc.. Balance Sheet: ALMS Debt, Cash & Liquidity
ALMS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Alumis Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-10.38 indicates the company is currently unprofitable.
ALMS Revenue Growth, EPS Growth & YoY Performance
ALMS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.7M | -$93.1M | $-0.74 |
| Q3 2025 | $2.1M | -$49.8M | $-1.06 |
| Q2 2025 | $2.7M | -$39.6M | $-0.61 |
| Q1 2025 | $17.4M | -$49.8M | $-1.82 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Alumis Inc.. Dividends, Buybacks & Capital Allocation
ALMS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alumis Inc.. (CIK: 0001847367)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ALMS
What is the AI rating for ALMS?
Alumis Inc.. (ALMS) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ALMS's key strengths?
Claude: Strong balance sheet with $567M stockholders' equity and effectively zero debt. Substantial cash reserves of $63.9M providing runway for continued R&D operations. ChatGPT: Strong liquidity with a 6.01x current ratio and meaningful cash relative to liabilities. No meaningful balance-sheet leverage, reducing refinancing and solvency pressure.
What are the risks of investing in ALMS?
Claude: Massive operating losses of -$98.4M against only $1.7M revenue indicates unsustainable burn rate unsupported by revenue. Negative operating cash flow of -$87.1M will deplete reserves within 12-18 months if business model does not change. ChatGPT: Operating model is highly unprofitable, with operating margin of -1615.5% and net margin of -679.9%. Cash burn is severe, with operating cash flow of -$297.62M and free cash flow of -$298.27M.
What is ALMS's revenue and growth?
Alumis Inc.. reported revenue of $1.7M.
Does ALMS pay dividends?
Alumis Inc.. does not currently pay dividends.
Where can I find ALMS SEC filings?
Official SEC filings for Alumis Inc.. (CIK: 0001847367) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ALMS's EPS?
Alumis Inc.. has a diluted EPS of $-0.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ALMS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Alumis Inc.. has a C grade with 66% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ALMS stock overvalued or undervalued?
Valuation metrics for ALMS: ROE of -16.4% (sector avg: 15%), net margin of -5,344.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ALMS's AI grade for 2026?
Our dual AI analysis gives Alumis Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ALMS's free cash flow?
Alumis Inc..'s operating cash flow is $-87.1M, with capital expenditures of $164.0K. FCF margin is -5,011.3%.
How does ALMS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5,344.8% (avg: 12%), ROE -16.4% (avg: 15%), current ratio 7.51 (avg: 2).